Physician profile
David Tamura
NPI 1295953123
$30,890.18
in general payments reported to CMS, 2019-2025
99 companies · $5,654 in 2025
The $5,654 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,771 · 2020: $7,047 · 2021: $4,995 · 2022: $3,082 · 2023: $3,331 · 2024: $4,010 · 2025: $5,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $780 · Education: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,584.32 |
| Consulting Fee | $780.00 |
| Education | $630.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $5,159.60 | 2019-2020 | |
| Array Biopharma INC | $2,028.05 | 2020-2025 | Braftovi, Xalkori, Mektovi |
| Pfizer INC. | $1,941.07 | 2019-2025 | |
| Janssen Biotech, INC. | $1,440.91 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $1,392.65 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $1,073.24 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Astellas Pharma US INC | $837.02 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Abbvie INC. | $826.53 | 2019-2025 | Venclexta, Creon |
| Geron Corporation | $807.17 | 2025 | Rytelo |
| Novartis Pharmaceuticals Corporation | $727.09 | 2019-2025 | |
| Genzyme Corporation | $725.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $683.71 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $659.28 | 2019-2025 | Opdivo, Reblozyl |
| Genentech USA, INC. | $649.09 | 2019-2025 | Venclexta, Tecentriq, Hemlibra |
| Eusa Pharma (US) LLC | $588.31 | 2019-2021 |
Show all 97 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $534.63 | 2019-2025 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $525.80 | 2019-2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $439.76 | 2022-2025 | Fotivda |
| Eisai INC. | $425.04 | 2019-2025 | |
| Lilly USA, LLC | $424.89 | 2019-2025 | Verzenio, Jaypirca |
| Exelixis INC. | $412.89 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $381.36 | 2019-2022 | |
| Puma Biotechnology, INC. | $354.12 | 2019-2025 | |
| Emd Serono, INC. | $325.11 | 2019-2025 | Bavencio, Tepmetko |
| Kite Pharma, INC. | $318.06 | 2020-2025 | Yescarta |
| Daiichi Sankyo INC. | $306.65 | 2020-2025 | Enhertu, Vanflyta, Datroway |
| Dendreon Pharmaceuticals LLC | $299.95 | 2019-2023 | Provenge |
| Karyopharm Therapeutics INC. | $279.33 | 2020-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $242.88 | 2023-2025 | |
| Celgene Corporation | $238.44 | 2021-2025 | Reblozyl, Opdualag |
| Coherus Oncology, INC. | $216.45 | 2020-2025 | Loqtorzi, Udenyca |
| Springworks Therapeutics, INC. | $199.78 | 2024-2025 | Ogsiveo |
| Gilead Sciences, INC. | $198.77 | 2019-2024 | Trodelvy |
| Aadi Bioscience, INC. | $193.64 | 2023 | Fyarro |
| Ipsen Biopharmaceuticals, INC | $186.41 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Tempus Ai, INC | $177.53 | 2024-2025 | Xt Cdx |
| Caris Mpi, INC. | $175.21 | 2025 | Mi Cancer Seek |
| US Oncology Corporate, INC. | $158.69 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $151.41 | 2021-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $140.83 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Taiho Oncology, INC. | $140.74 | 2020-2025 | |
| Csl Behring | $138.88 | 2024 | Hemgenix |
| Mirati Therapeutics, INC. | $138.43 | 2023-2024 | Krazati |
| Sun Pharmaceutical Industries INC. | $129.85 | 2019-2024 | Odomzo, Yonsa |
| Cardinal Health 108 LLC | $128.37 | 2022 | |
| Stemline Therapeutics INC. | $124.68 | 2023-2025 | Orserdu |
| Tersera Therapeutics LLC | $123.06 | 2023-2025 | Zoladex |
| Blueprint Medicines Corporation | $121.81 | 2020-2022 | |
| Biomarin Pharmaceutical INC. | $119.86 | 2025 | Roctavian |
| Deciphera Pharmaceuticals INC. | $119.51 | 2021-2024 | Qinlock |
| Pharmacosmos Therapeutics INC. | $119.05 | 2024-2025 | Monoferric, Cosela |
| Verastem, INC. | $112.31 | 2019 | |
| Agios Pharmaceuticals, INC. | $105.81 | 2019-2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $105.25 | 2023-2025 | Rolvedon |
| Acrotech Biopharma INC. | $103.46 | 2021-2025 | Beleodaq, Ryzneuta |
| Kyowa Kirin, INC. | $100.05 | 2023-2025 | Poteligeo |
| Glaxosmithkline, LLC. | $98.72 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $98.10 | 2022-2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $96.00 | 2023 | |
| Novocure INC. | $95.94 | 2021-2024 | Optune |
| Dova Pharmaceuticals | $94.11 | 2019-2021 | |
| Epizyme, INC. | $92.42 | 2020-2022 | |
| Novo Nordisk INC | $92.15 | 2020-2025 | Novoeight, Novoseven, Rebinyn |
| Servier Pharmaceuticals LLC | $89.88 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.79 | 2022-2025 | Ninlaro |
| Sobi, INC | $85.33 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $84.56 | 2024-2025 | Clonoseq |
| Genmab U.S., INC. | $80.50 | 2024-2025 | Epkinly |
| Beone Medicines USA, INC. | $78.48 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.60 | 2019-2024 | Gilotrif |
| Apellis Pharmaceuticals, INC. | $68.37 | 2023-2024 | Empaveli |
| Azurity Pharmaceuticals, INC. | $64.48 | 2024-2025 | Danziten, Vivimusta |
| Foundation Medicine, INC. | $64.23 | 2020-2022 | |
| Syndax Pharmaceuticals, INC. | $60.70 | 2025 | |
| Recordati_rare_diseases_inc. | $58.07 | 2024-2025 | Sylvant |
| Mylan Institutional INC. | $50.14 | 2023 | Fulphila, Ogivri |
| Immunitybio, INC. | $42.17 | 2025 | |
| Janssen Scientific Affairs, LLC | $37.87 | 2019-2025 | Erleada, Balversa, Akeega |
| Aurobindo Pharma USA, INC. | $37.47 | 2020 | |
| Chiesi USA, INC. | $35.43 | 2025 | Ferriprox |
| Beigene USA, INC. | $33.52 | 2025 | Tevimbra |
| Alnylam Pharmaceuticals INC. | $29.30 | 2024 | Givlaari |
| Pharmaessentia USA Corporation | $26.83 | 2025 | Besremi |
| Ferring Pharmaceuticals INC. | $24.84 | 2025 | Adstiladrin |
| G1 Therapeutics, INC. | $24.30 | 2022 | |
| Verity Pharmaceuticals INC. | $24.04 | 2025 | Trelstar |
| Partner Therapeutics, INC. | $23.03 | 2019 | |
| Fresenius Kabi USA, LLC | $20.79 | 2023 | Stimufend |
| Myriad Genetic Laboratories, INC. | $20.71 | 2021 | |
| Fennec Pharmaceuticals, INC. | $19.88 | 2025 | Fyarro |
| Morphosys, US INC. | $18.66 | 2021 | |
| Menarini Silicon Biosystems, INC. | $18.41 | 2025 | |
| Horizon Therapeutics Plc | $16.59 | 2021 | |
| Allergan, INC. | $14.90 | 2019 | |
| Clovis Oncology, INC. | $12.39 | 2022 | |
| Adc Therapeutics America, INC. | $12.00 | 2022 | |
| Secura Bio, INC. | $9.79 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Rytelo $807Xtandi $781Imfinzi $500Enhertu $393Erleada $383Jakafi $346Cabometyx $322Padcev $260Keytruda $252Xpovio $244Fotivda $230Talzenna $226Ibrance $220Fyarro $214Epkinly $212Venclexta $211Ogsiveo $200Lenvima $193Zepzelca $190Mi Cancer Seek $175Pluvicto $174Lutathera $174Kisqali $172Niktimvo $166Orgovyx $159Elrexfio $155Verzenio $149Jevtana $148Reblozyl $139Hemgenix $139Krazati $138Pemazyre $138Monjuvi $138Scemblix $137Rybrevant $125Orserdu $125Zoladex $123Roctavian $120Xt Cdx $116Calquence $112Tukysa $112Adcetris $112Opdivo $108Jaypirca $107Rolvedon $105Welireg $104Braftovi $101Monoferric $101Poteligeo $100Bosulif $98.82Udenyca $94.65Inqovi $93.61Lonsurf $93.61Yescarta $93.55Gavreto $89.44Tavalisse $88.31Rezlidhia $88.31Promacta $88.25Onivyde $87.00Carvykti $85.74Lynparza $85.52Clonoseq $84.56Imbruvica $81.78Tecentriq $80.28Fabhalta $79.04Brukinsa $78.48Ninlaro $73.00Xalkori $71.79Mektovi $71.79Lorbrena $71.79Optune $71.25Qinlock $70.80Empaveli $68.37Nerlynx $67.37Pyrukynd $66.31Sarclisa $63.47Comirnaty $63.27Yonsa $62.96Odomzo $62.96Tibsovo $61.59Libtayo $59.98Sylvant $58.07Vanflyta $57.80Tasigna $57.56Inlyta $55.07Vonjo $54.22Emrelis $54.01Ziihera $52.75Ultomiris $52.69Loqtorzi $52.43Fulphila $50.14Ogivri $50.14Beleodaq $49.54Danziten $47.87Tecvayli $47.30Gilotrif $47.19Trodelvy $46.62Novoseven $43.68Novoeight $43.68Ojjaara $43.01
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tamura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.